Antitumor effects of BI-D1870 on human oral squamous cell carcinoma

Cancer Chemotherapy and Pharmacology

Volumn 73, Issue 2, 2014, Pages 237-247

  Chiu, Chang Fang ^a,c   Bai, Li Yuan ^a,c   Kapuriya, Naval ^d   Peng, Shih Yuan ^b   Wu, Chia Yung ^b   Sargeant, Aaron M ^e   Chen, Michael Yuanchien ^a,b   Weng, Jing Ru ^b  

^a CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

^d OHIO STATE UNIVERSITY   (United States)

^e CHARLES RIVER LABORATORIES   (United States)

Author keywords

Autophagy; BI D1870; Oral cancer; Reactive oxygen species; RSK

Indexed keywords

2 [(3,5 DIFLUORO 4 HYDROPHENYL)AMINO] 8 ISOPENTYL 5,7 DIMETHYL 7,8 DIHYDROPTERIDIN 6(5H) ONE; ANTINEOPLASTIC AGENT; BID 1870; CASPASE; MITOGEN ACTIVATED PROTEIN KINASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN P21; PROTEIN P90; REACTIVE OXYGEN METABOLITE; S6 KINASE; UNCLASSIFIED DRUG; Y BOX BINDING PROTEIN 1;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHAGY; CANCER CELL CULTURE; CELL NUCLEUS; CONCENTRATION RESPONSE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; ENDOPLASMIC RETICULUM STRESS; ENZYME ACTIVATION; FLOW CYTOMETRY; G2 PHASE CELL CYCLE CHECKPOINT; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; KERATINOCYTE; M PHASE CELL CYCLE CHECKPOINT; MOUTH SQUAMOUS CELL CARCINOMA; MTT ASSAY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

AUTOPHAGY; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; ENDOPLASMIC RETICULUM STRESS; HEAD AND NECK NEOPLASMS; HUMANS; MAP KINASE SIGNALING SYSTEM; MICROSCOPY, CONFOCAL; MOUTH NEOPLASMS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTO-ONCOGENE PROTEINS C-AKT; PTERIDINES; REACTIVE OXYGEN SPECIES; RIBOSOMAL PROTEIN S6 KINASES, 90-KDA; TRANSFECTION;

EID: 84896048237     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-013-2349-9     Document Type: Article

References (30)

1. Vermorken JB, Remenar E, van Herpen C, Gorlia T, Mesia R, Degardin M, Stewart JS, Jelic S, Betka J, Preiss JH, van den Weyngaert D, Awada A, Cupissol D, Kienzer HR, Rey A, Desaunois I, Bernier J, Lefebvre JL (2007) Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 357:1695-1704 (Pubitemid 350005151)
2. Anjum R, Blenis J (2008) The RSK family of kinases: emerging roles in cellular signalling. Nat Rev Mol Cell Biol 9:747-758
3. Frodin M, Gammeltoft S (1999) Role and regulation of 90 kDa ribosomal S6 kinase (RSK) in signal transduction. Mol Cell Endocrinol 151:65-77
4. Chen RH, Sarnecki C, Blenis J (1992) Nuclear localization and regulation of erk- and rsk-encoded protein kinases. Mol Cell Biol 12:915-927
5. Kang S, Elf S, Lythgoe K, Hitosugi T, Taunton J, Zhou W, Xiong L, Wang D, Muller S, Fan S, Sun SY, Marcus AI, Gu TL, Polakiewicz RD, Chen ZG, Khuri FR, Shin DM, Chen J (2010) p90 ribosomal S6 kinase 2 promotes invasion and metastasis of human head and neck squamous cell carcinoma cells. J Clin Invest 120:1165-1177
6. Bain J, Plater L, Elliott M, Shpiro N, Hastie CJ, McLauchlan H, Klevernic I, Arthur JS, Alessi DR, Cohen P (2007) The selectivity of protein kinase inhibitors: a further update. Biochem J 408:297-315
7. Sapkota GP, Cummings L, Newell FS, Armstrong C, Bain J, Frodin M, Grauert M, Hoffmann M, Schnapp G, Steegmaier M, Cohen P, Alessi DR (2007) BI-D1870 is a specific inhibitor of the p90 RSK (ribosomal S6 kinase) isoforms in vitro and in vivo. Biochem J 401:29-38 (Pubitemid 46114597)
8. Nguyen TL (2008) Targeting RSK: an overview of small molecule inhibitors. Anticancer Agents Med Chem 8:710-716
9. Chambard JC, Lefloch R, Pouyssegur J, Lenormand P (2007) ERK implication in cell cycle regulation. Biochim Biophys Acta 1773:1299-1310 (Pubitemid 47125974)
10. Stratford AL, Fry CJ, Desilets C, Davies AH, Cho YY, Li Y, Dong Z, Berquin IM, Roux PP, Dunn SE (2008) Y-box binding protein-1 serine 102 is a downstream target of p90 ribosomal S6 kinase in basal-like breast cancer cells. Breast Cancer Res 10:R99
11. Fang J, Seki T, Maeda H (2009) Therapeutic strategies by modulating oxygen stress in cancer and inflammation. Adv Drug Deliv Rev 61:290-302
12. Kim I, Xu W, Reed JC (2008) Cell death and endoplasmic reticulum stress: disease relevance and therapeutic opportunities. Nat Rev Drug Discov 7:1013-1030
13. Lin Y, Wang Z, Liu L, Chen L (2011) Akt is the downstream target of GRP78 in mediating cisplatin resistance in ER stress-tolerant human lung cancer cells. Lung Cancer 71:291-297
14. Mathew R, Karantza-Wadsworth V, White E (2007) Role of autophagy in cancer. Nat Rev Cancer 7:961-967 (Pubitemid 350165856)
15. Scherz-Shouval R, Elazar Z (2011) Regulation of autophagy by ROS: physiology and pathology. Trends Biochem Sci 36:30-38
16. Tanimura S, Hashizume J, Kurosaki Y, Sei K, Gotoh A, Ohtake R, Kawano M, Watanabe K, Kohno M (2011) SH3P2 is a negative regulator of cell motility whose function is inhibited by ribosomal S6 kinase-mediated phosphorylation. Genes Cells 16:514-526
17. Petrella BL, Armstrong DA, Vincenti MP (2011) CCAAT-enhancer-binding protein beta activation of MMP-1 gene expression in SW1353 cells: independent roles of extracellular signal-regulated and p90/ribosomal S6 kinases. J Cell Physiol 226:3349-3354
18. Chen S, Mackintosh C (2009) Differential regulation of NHE1 phosphorylation and glucose uptake by inhibitors of the ERK pathway and p90RSK in 3T3-L1 adipocytes. Cell Signal 21:1984-1993
19. Mishima K, Yamada E, Masui K, Shimokawara T, Takayama K, Sugimura M, Ichijima K (1998) Overexpression of the ERK/MAP kinases in oral squamous cell carcinoma. Mod Pathol 11:886-891 (Pubitemid 28440886)
20. Johnson GL, Lapadat R (2002) Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 298:1911-1912 (Pubitemid 35425238)
21. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F, Lehmann B, Terrian DM, Milella M, Tafuri A, Stivala F, Libra M, Basecke J, Evangelisti C, Martelli AM, Franklin RA (2007) Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 1773:1263-1284 (Pubitemid 47125967)
22. Das N, Majumder J, DasGupta UB (2000) ras gene mutations in oral cancer in eastern India. Oral Oncol 36:76-80
23. Chang SE, Bhatia P, Johnson NW, Morgan PR, McCormick F, Young B, Hiorns L (1991) Ras mutations in United Kingdom examples of oral malignancies are infrequent. Int J Cancer 48:409-412
24. Mishima K, Inoue K, Hayashi Y (2002) Overexpression of extracellular-signal regulated kinases on oral squamous cell carcinoma. Oral Oncol 38:468-474 (Pubitemid 34756732)
25. Partridge M, Gullick WJ, Langdon JD, Sherriff M (1988) Expression of epidermal growth factor receptor on oral squamous cell carcinoma. Br J Oral Maxillofac Surg 26:381-389
26. Werkmeister R, Brandt B, Joos U (2000) Clinical relevance of erbB-1 and -2 oncogenes in oral carcinomas. Oral Oncol 36:100-105
27. Yu T, Wu Y, Helman JI, Wen Y, Wang C, Li L (2011) CXCR4 promotes oral squamous cell carcinoma migration and invasion through inducing expression of MMP-9 and MMP-13 via the ERK signaling pathway. Mol Cancer Res 9:161-172
28. Yang LC, Yang SH, Tai KW, Chou MY, Yang JJ (2004) MEK inhibition enhances bleomycin A5-induced apoptosis in an oral cancer cell line: signaling mechanisms and therapeutic opportunities. J Oral Pathol Med 33:37-45
29. Hu P, Han Z, Couvillon AD, Exton JH (2004) Critical role of endogenous Akt/IAPs and MEK1/ERK pathways in counteracting endoplasmic reticulum stress-induced cell death. J Biol Chem 279:49420-49429 (Pubitemid 39625828)
30. Zhang LJ, Chen S, Wu P, Hu CS, Thorne RF, Luo CM, Hersey P, Zhang XD (2009) Inhibition of MEK blocks GRP78 up-regulation and enhances apoptosis induced by ER stress in gastric cancer cells. Cancer Lett 274:40-46